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Background: Gaps in the HIV care continuum contribute to suboptimal individual health outcomes and increased
risk of HIV transmission at the population level. Implementation science studies are needed to evaluate clinic-based
interventions aimed at improving retention of patients across the continuum.
Methods/design: Link4Health uses an unblended cluster site-randomized design to evaluate the effectiveness of a
combination intervention strategy (CIS) as compared to standard of care on linkage to and retention in care among
HIV-diagnosed adults in Swaziland. The CIS intervention targets a multiplicity of structural, behavioral, and biomedical
barriers through five interventions: (1) point-of-care CD4 testing at time of HIV testing, (2) accelerated antiretroviral
therapy (ART) initiation for eligible patients, (3) mobile phone appointment reminders, (4) care and prevention
packages, and (5) non-cash financial incentives for linkage and retention. The unit of randomization is a network of HIV
clinics inclusive of a secondary facility coupled with an affiliated primary facility. Ten study units were randomized
based on implementing partner, geographic location, and historic volume of HIV patients. Target enrollment was 2200
individuals, each to be followed for 12 months. Eligibility criteria includes HIV-positive test, age >18 years, willing to
receive HIV care at a clinic in the study unit and consent to study procedures. Exclusion criteria included previous HIV
care in the past 6 months, planning to leave the community, and current pregnancy.
The primary study outcome is linkage within 1 month and retention at 12 months after testing HIV positive. Secondary
outcomes include viral load suppression at 12 months, time to ART eligibility and initiation, participant acceptability,
and cost-effectiveness. The trial status is that study enrollment is complete and follow-up procedures are ongoing.
Discussion: Link4Health evaluates a novel and pragmatic combination intervention strategy to improve linkage to and
retention in care among adults with HIV in Swaziland. If the strategy is found to be effective, this study has the
potential to inform HIV service delivery in resource-limited settings.
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Patient engagement and retention in the HIV care
continuum is essential to optimize health outcomes for the
individual and to reduce HIV transmission to others [1–3].
Linkage from HIV testing to HIV care is the first step
in the continuum and is essential for accessing appro-
priate HIV care and treatment interventions [4]. Re-
tention in ongoing HIV care is needed for clinical and
laboratory monitoring of disease progression, assess-
ment for eligibility for antiretroviral therapy (ART),
initiation of ART when eligible, effective prevention of
mother-to-child transmission (PMTCT), and provision
of support and prevention [4–8]. Multiple studies con-
ducted in sub-Saharan Africa report high attrition
from testing to linkage to care and suboptimal reten-
tion in ongoing care [9–18].
While several studies have evaluated the effect of an
individual intervention on one step in the HIV care
continuum, few have evaluated a combination ap-
proach that includes multiple interventions bundled
into a coherent strategy that would target numerous
barriers along the continuum [19]. A combination ap-
proach must include structural, biomedical, and be-
havioral interventions that address specific barriers
reported in the literature [14, 16, 20–30]. Additionally,
there is the need for implementation science research
to evaluate proposed combination approaches in a
“real-life” context to provide pragmatic information
on uptake of interventions, feasibility, and acceptabil-
ity [31, 32].
Swaziland is a small country in Southern Africa with
the world’s most severe HIV epidemic, and HIV-related
illness is the leading cause of death in the country. It
has a population of 1.1 million persons, an estimated
adult (age 18–49 years) HIV prevalence of 31 % and
an estimated incidence of 2.4 % [33–35]. The coun-
try has made impressive advances in responding to
the epidemic. In 2011 at the time of this study start,
93,295 adults had cumulatively been initiated on
ART across the country, and by 2013, this number
increased to 133,420 [36]. Nevertheless, rates of link-
age to care and retention at 12 months after ART
initiation remain suboptimal [37, 38]. Swaziland’s
Ministry of Health is committed to improving reten-
tion along the HIV care continuum in order to
decrease the impact of HIV on morbidity and mor-
tality as well as to decrease the alarming incidence
rate of HIV.
We describe the design of Link4Health, an implemen-
tation science study that aims to assess the effectiveness
of a combination strategy comprised of five evidence-
based interventions designed to improve linkage to and
retention in care among adults newly tested HIV posi-
tive in Swaziland.Evidence for selected interventions
Each intervention used in the combination strategy was
selected based on being practical and having prior evi-
dence supporting its use for improving linkage to and/or
retention in HIV care in a resource-limited setting.
The first intervention, point-of-care CD4+ count
testing, when done at the time of receipt of result of
an HIV-positive test, reduces the number of visits
needed to identify patients who are eligible for ART
from multiple visits to a single visit. As such, it ad-
dresses a structural barrier implicit in the need for
multiple visits previously required prior to ART initi-
ation. Several studies have reported higher linkage
rates with point-of-care CD4+ count testing as com-
pared to traditional CD4+ count testing [39–42]. In
addition, provision of a CD4+ count result to a pa-
tient at the time of HIV diagnosis may serve to mo-
tivate faster linkage to care, especially for a patient
who is found to be eligible for treatment.
The second intervention in the combined strategy, ac-
celerated ART initiation for eligible patients, reduces the
number of clinic visits required prior to initiation among
eligible patients. This is important as high mortality has
been noted among HIV-infected individuals who fail to
engage in care, particularly among those with advanced
disease [12, 43–45].
The third intervention in the combined strategy is the
use of short message service (SMS) reminders for clinic
appointments. SMS reminders have been used in HIV
care and other chronic disease management to improve
health communication and patient adherence [46–54].
The fourth intervention is a basic care and prevention
package which provides counseling and health commod-
ities such as condoms, pillboxes, and soap with the goal
of improving health prevention and health outcomes
[55–59]. A similar intervention was evaluated in Uganda
and was associated with high rates of cotrimoxazole use,
condom use, and HIV testing of family members [55].
The fifth intervention is non-cash financial incentives.
There has been great interest in the use of financial
incentives as a structural intervention to achieve posi-
tive health behaviors [60–66]. In this study, the non-
cash financial incentives are targeted at mitigating the
costs of care which include transport costs and oppor-




Link4Health is a cluster site-randomized trial. The unit
of randomization is a network of secondary HIV clinics
paired with an affiliated primary-level HIV clinic, which
is referred to as a study unit (Fig. 1). The study unit re-
flects the ongoing process of decentralization of HIV
Fig. 1 Link4Health study units
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Swaziland [38]. Ten study units were selected from the
11 existing secondary facilities in the country. The largest
primary-level facility affiliated with each selected secondary
facility was selected based on HIV program size (i.e.,
number of HIV patients in follow-up at the site based
on 18-month historic data, with special attention given
to the most recent 6 months). Study units were ran-
domized to the combination intervention strategy (CIS)
or standard of care (SOC) strategy using matched-pair
randomization balanced by the following factors: facility
location (rural, urban), expected number of adults enrolled
in HIV care at each facility per month, and implementing
partner supporting the facility (Table 1). Sites within
matched pairs were randomized to receive either CIS
or SOC by generating a random integer using Microsoft
Excel, taking the alphabetically first site name if the ran-
dom integer drawn was 1, and the alphabetically second
site name if the random integer drawn was 2.Individuals who tested HIV positive at HIV testing
sites located at the study unit received post-test coun-
seling and were referred to the study by clinic staff.
Thereafter, the study research staff provided an over-
view of the study, conducted eligibility screening, and
conducted informed consent procedures. Study eligi-
bility criteria included the following: HIV-positive test,
≥18 years of age, willing to receive HIV care at a
clinic in the study unit, and consent to study proce-
dures. Study exclusion criteria included the following:
planning on leaving the community during the study
period for more than 6 months, enrolled in HIV care
and/or initiated ART in the past 6 months, currently
on ART, does not speak English or SiSwati, or current
pregnancy.
Study objectives and outcomes
The primary study objective was to evaluate the effect-
iveness of the CIS compared to SOC on the combined
Table 1 Study unit matched pairs
Matched pair Study unit Study arm Implementing partner Location
1 1 SOC Partner A Urban
2 CIS Partner A Urban
2 3 SOC Partner A Urban
4 CIS Partner A Urban
3 5 SOC Partner A Rural
6 CIS Partner A Rural
4 7 SOC Partner A Rural
8 CIS Partner A Rural
5 9 CIS Partner B Urban
10 SOC Partner B Urban
SOC standard of care, CIS combination intervention strategy
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HIV-positive test and retention in care at 12 months
among adults diagnosed with HIV. Linkage to care was
defined by at least one visit to HIV clinic with comple-
tion of an intake assessment including medical history
and physical exam. Retention in care at 12 months after
HIV testing was defined as a clinic visit within 90 days
prior to the end of the study follow-up period.
The secondary objectives included the evaluation of
the effectiveness of CIS compared to SOC with regard to
the following: linkage to care within 1 month after test-
ing HIV positive, retention in care at 12 months after
testing HIV positive, time to ART eligibility and ART
initiation, viral load suppression at 12 months after HIV
testing, disease progression, patient acceptability, and
cost-effectiveness. Additionally, the effect of sociodemo-
graphic and clinical determinants on key study outcomes
was to be assessed.
Study interventions
Standard of care
At study units assigned to the SOC arm of the study,
participants were managed as per country guidelines.
After testing HIV positive, individuals received post-test
counseling and were referred to an HIV clinic using a
national referral form that documents the patient’s iden-
tification and HIV status. Patients who linked to HIV
care received clinical and laboratory assessments for the
determination of ART eligibility, including CD4+ count
testing and hematology and chemistry tests, and were
instructed to return to the clinic in 1 to 2 weeks to re-
ceive their results. Upon return, those found eligible for
ART initiation received three counseling sessions. The
time interval from eligibility determination to ART initi-
ation typically has been 1 to 2 months. All patients were
given cotrimoxazole prophylaxis and those not eligible
for ART were instructed to return every 3 months to the
clinic, while those who initiated ART returned to theclinic every month for 6 months, and then every
3 months if they were stable on treatment. Peer coun-
selors were encouraged to call patients within 7 days of
a missed appointment; however, these procedures were
often not consistently applied. Condoms and informa-
tional materials were available for all patients at HIV
clinic visits.
Combination intervention strategy
Participants at study units assigned to the CIS study arm
received five evidence-based interventions in addition to
SOC interventions. The five interventions include the fol-
lowing: (1) point-of-care CD4+ count testing on the same
day as HIV diagnosis, (2) accelerated ART initiation for
eligible patients with CD4+ count <350 cells/μL, the pre-
vailing ART eligibility threshold during the conduct of the
study, (3) mobile phone appointment reminders, (4) care
and prevention bags, and (5) non-cash financial incentives
for linkage and retention. Table 2 shows the interventions
included in the study, the type of barrier addressed, and
the target step in the HIV care continuum. Clinic staff at
study units assigned to CIS were trained on each of these
interventions and the importance of their provision to all
study participants at their site.
1) Point-of-care CD4+ count testing. Each participant at
sites randomized to CIS received a point-of-care
CD4+ count test immediately after testing HIV
positive. The CD4+ count test was conducted by
the study staff and took approximately 20 min to
process. CD4+ count results and their implications
were provided to the participant, and a copy was
placed in the patient’s national referral form for HIV
care. Regardless of the CD4+ count result, all
participants were encouraged to link to HIV
care within 1 week of receiving the results.
2) Accelerated ART initiation for eligible participants.
This intervention streamlined the preparatory
procedures required for ART initiation by
consolidating the ART counseling sessions into
two sessions, as compared to three in standard of
care, in order to enable ART initiation within
1 week of diagnosis. At sites assigned to CIS, the
first ART preparatory counseling session was given
at the time of receiving the point-of-care CD4+
count result at the HIV test site. The second session
was given by the clinic staff at the HIV care site, at the
first visit upon linkage to care by the participant.
Clinic staff collected samples for the required baseline
laboratory tests per national guidelines. Clinicians
were encouraged to initiate ART at this first care visit,
rather than awaiting the results of these laboratory
tests in participants with no comorbid conditions. For
participants that needed further counseling and/or
Table 2 Study interventions, type of intervention, and target step in the HIV care continuum









• Point-of-care CD4 assays available in some
primary care clinics and some secondary health
centers/hospitals for patients enrolled in HIV care
but only used once a patient has linked to care
• Point-of-care CD4 assays at the HIV testing






• Turnaround time immediate
• All clinics have CD4 (Cyflow, FACS Caliber) availability
after linkage to HIV care in the clinic or lab
• Turnaround time approximately 2 weeks
Accelerated
ART initiation
• ART initiation per national guidelines for patients
with CD4 ≤350 cells/μL or WHO stage III/VI
• Accelerated ART initiation for patients with







• Requires 3 counseling sessions and receipt of
baseline lab tests
• 2 counseling sessions (one at the time of HIV
testing and another at the first HIV clinic visit), and
collection of blood for other baseline lab tests, but
ART initiation prior to return of results for patients
who do not meet the criteria for waiting for receipt
of lab results prior to ART initiation




• Telephone call within 7 days of missed
appointment for ART patients only
• Short message service (SMS) (or voice if illiterate)




• SMS (or voice if illiterate) reminder within 7 days




• Cotrimoxazole prescribed for all patients once
enrolled in HIV care
• Basic care and prevention package provided
approximately every 3 months. Package includes
condoms, soap, cotrimoxazole, pillbox, and pictorial
education about the use of materials and HIV, such









• None • Non-cash financial incentive (mobile airtime)
provided for linkage within 1 month of testing and
retention at 6 and 12 months
Structural Linkage and
retention
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discretion of the clinician. Participants who initiated
ART received a 2-week supply of medications per
national guidelines. Baseline laboratory results were
reviewed by the study staff with the clinic staff soon
after availability, and if any abnormality was noted,
participants were contacted to return to the clinic.
After initiating ART, all follow-up visits followed
national guidelines, similar to the standard of care
procedures.
3) Mobile phone appointment reminders. All
participants at sites assigned to CIS received
appointment reminders via mobile phone SMS, or
voice message reminders for illiterate participants, to
encourage linkage to care and completion of scheduled
clinic visits. Reminders were sent to the participant’s
phone or on a friend or relative’s phone per participant
preference. The reminders did not refer to HIV or
reveal any personal information. An example message
is: “Good day – This is a reminder about your visit at
[health facility] tomorrow. We look forward to seeing
you then.” SMS were sent from a central server 1 dayprior to scheduled clinic visit date for all participants.
For participants who missed appointments, a text
message was sent within 7 days to encourage the
participant to return to the clinic.
4) Basic care and prevention package. All participants
at sites assigned to CIS received a package of
commodities and informational materials upon
linkage to care and once every 3 months thereafter
during the study period. This package was designed
to offer an opportunity to have further counseling
on HIV care through provision of commodities that
were deemed of value by the patients. Commodities
in the package included condoms, a pillbox, soap,
toothbrush and paste, cotrimoxazole tablets, and an
appointment calendar. The health counseling that
accompanied each package used existing national
health information and educational materials (i.e.,
pamphlets, pictures) that focused on medication
adherence, family planning, tuberculosis screening
and cough hygiene, and nutrition.
5) Non-cash financial incentive (FI). All participants at
sites assigned to CIS who linked to care within
McNairy et al. Implementation Science  (2015) 10:101 Page 6 of 91 month of HIV testing and those who completed
HIV care clinic visits at 6 and 12 months after HIV
testing received a non-cash FI in the form of prepaid
mobile phone airtime vouchers. Each FI consisted of
80 Swaziland Emalangeni ($8–10), an amount selected
based on the estimated cost of traveling to the clinic
and with consultation with key stakeholders in the
country.Data collection
All participants completed a baseline interview, at the
time of study enrollment, which included information
on sociodemographics, HIV history, barriers to care,
travel time to clinic, depression, social and family sup-
port, and HIV-related knowledge. Follow-up interviews
were conducted at home at 1 and 12 months after en-
rollment to collect information on changes in sociode-
mographic characteristics, utilization of HIV services
including self-reported linkage to care and visit comple-
tion, and acceptability of the study interventions. A CD4
+ cell count was obtained at 12 months. Additional clin-
ical and laboratory data were extracted from paper-
based patient medical charts. Facility assessment surveys
were conducted at the beginning of the study and every
6 months to document any changes in clinical services
that occurred during the study period that may influence
study outcomes. Costs of delivering the SOC and CIS
were estimated based on the cost of outpatient HIV care,
the cost of hospitalization, and the cost of delivering
each intervention component.Sample size and power calculations
We estimated that 35 % of participants in the SOC study
arm would achieve the combined primary outcome
(assuming 50 % link to HIV care within 1 month and
70 % of those linking within 1 month are retained
12 months after study enrollment). We estimated that
approximately 2750 adults would be eligible for study
enrollment based on historic testing volume, the pro-
portion testing HIV positive at the study units from
2010 to 2011. Assuming 80 % of eligible individuals
consent to enroll in the study, we estimated an average
enrollment of 220 participants per study unit or 2200
in total with 1100 per study arm.
With this sample size and five study units per study
arm, we estimated the minimum difference in the pri-
mary outcome we could detect with 80 % power using a
two-sided Farrington and Manning Likelihood Score
Test [19], assuming an interclass correlation coefficient
of 0.05. Estimates were made using the Power and Sample
Size (Pass 8.0) software program. With these assumptions,
the study has 80 % power to detect an absolute increase of
20 % or more in the CIS versus SOC arm on the primaryoutcome of linkage within 1 month and retention at
12 months.Statistical methods
An intent-to-treat analysis was planned to compare
the relative risk of achieving the primary outcome of
linkage to care within 1 month and retention in care
at 12 months after HIV testing. The effectiveness of
CIS compared to SOC will also be assessed on sec-
ondary outcomes including the following: linkage to
care within 1 month; retention 12 months after HIV
diagnosis; and time from ART eligibility to ART initi-
ation, viral load suppression 12 months after HIV
diagnosis, disease progression, and cost-effectiveness.
Sub-distribution hazard models, treating death as a
competing risk for ART initiation, are to be used to
compare the time from eligibility to initiation of ART
between participants receiving CIS and SOC, with
participants transferring or becoming lost to follow-
up after ART eligibility but before initiation censored
at their date of transfer or their last recorded visit.
Robust sandwich estimates of variance will be used to
account for correlation within study units. Sociode-
mographic and clinical determinants of the primary
and secondary outcomes are to be analyzed to exam-
ine whether the CIS differentially impacts outcomes
within strata by sociodemographic and clinical charac-
teristics (e.g., age, sex, HIV disease stage, CD4+ count,
tuberculosis, and pregnancy status). We will conduct
covariate-adjusted generalized linear mixed models if
important differences are observed between study
arms in order to assess the degree to which these differ-
ences influence outcomes. For cost-effectiveness analysis,
a model will be created to estimate the effect of CIS on
health benefits and costs. Differences in life expectancy,
quality-adjusted life years, and infections averted between
CIS and SOC arms will be estimated using inputs from
the study.Ethical considerations and study guidance
This study was approved by the institutional review
boards at Columbia University, the US Centers for Disease
Control and Prevention, and the Swaziland Scientific and
Ethics Committee.
An advisory board was established to guide and moni-
tor the study. This included representatives from the
Ministry of Health, implementing partners and other
stakeholders. The board meets quarterly and reviews
challenges on clinical implementation of procedures, re-
finement of interventions, and discussion of the poten-
tial influence of study findings on HIV program design
and planning.
McNairy et al. Implementation Science  (2015) 10:101 Page 7 of 9Trial status
The study commenced enrollment in August 2013 and
has completed enrollment of participants. The study is
currently completing 12-month follow-up procedures in-
cluding questionnaires, laboratory tests, and medical
record abstraction.
Discussion
The Link4Health study leverages a combination of evi-
dence-based interventions, which target multiple known
barriers hindering linkage to and retention in HIV care.
Aligned with the goals of implementation science, this
study evaluates the combination strategy in a real-life clin-
ical setting in Swaziland. The interventions were adapted
to fit the unique characteristics of this setting including
the health system structure, norms of practice, physical
space, and available staffing at the health facilities. With
such an approach, the goal is to obtain generalizable
knowledge about the feasibility and effectiveness of
implementing such a strategy, which could be applied
in a range of settings with similar implementation contexts.
We selected a site-randomized study design as it is con-
ducive to the implementation science approach in which
study interventions are delivered at the clinic level. It is
deemed more feasible for clinic staff at a site to provide all
their patients with the same package of interventions, ver-
sus the situation in individual-randomized design with the
complexity entailed in staff providing one patient with one
intervention strategy versus another. In addition, while
there is yet no evidence to suggest that the experimental
intervention in this study will be superior to standard of
care, individual randomization may have resulted in indi-
viduals randomized to that arm to perceive themselves as
receiving an inferior strategy which may influence their
health-seeking behaviors and ultimately the key study end-
points of linkage and retention.
The study design has several strengths. The study in-
cludes all regions in Swaziland, and study procedures
largely mimic the HIV care structure and processes in
the country. The study units took into account a com-
mon pattern of health facility structure noted in sub-
Saharan Africa with smaller facilities linked to a larger
facility. Eligibility criteria were selected to be broad with
the aim to include as many patients as possible for
generalizability. Accelerated ART was administered by
clinic staff, rather than study staff, requiring minor ad-
justments in the traditional clinic procedures and patient
flow. The cost-effectiveness analysis will help policy makers
have practical budget information to guide decision-making
about the intervention.
Limitations of the study design included the evaluation
of retention at 12 months, which would not be sufficient
to evaluate the longer-term effect of the intervention.
Additionally, Swaziland has a limited number of studyunits, which reduces the ability to completely control for
cluster overlap or provide alternate study units should a
study unit halt HIV services. Finally, the study design
does not allow for evaluation of the effectiveness of each
component intervention in the CIS which would require
a study of substantially larger size. However, results from
this study can be compared to other studies in Swaziland
evaluating different individual interventions aimed at
improving linkage and retention in HIV care.
Conclusion
The Link4Health study aims to improve linkage of HIV-
positive patients to care and subsequently their retention
in care. These two elements in the HIV care continuum
are acknowledged to be of profound importance in
achieving the impact of effective HIV programming on
patient outcomes and reduced transmission at the popu-
lation level. With the largest HIV burden in the world,
Swaziland could greatly benefit from identification of an
effective strategy for linkage and retention in its efforts
to control its HIV epidemic. If shown to be effective, the
combination intervention strategy may also serve to en-
hance the quality of the HIV care continuum in other
countries in sub-Saharan Africa and beyond.
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